Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | RXRA | P19793 | 1/20 | 0.32 |
| ▸ | RXRB | P28702 | 1/20 | 0.32 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.31 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13507849 | 0.93 | L3MBTL1 (0.33) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507361 | 0.92 | RXRA (0.34) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507350 | 0.88 | RXRA (0.40) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507870 | 0.85 | RXRA (0.40) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507356 | 0.85 | AKT1 (0.38) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507199 | 0.84 | RXRA (0.33) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507096 | 0.83 | RXRA (0.37) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507195 | 0.83 | NTSR1 (0.34) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507271 | 0.83 | CHEK1 (0.34) | L3MBTL1NPC1RAB9ARXRARXRB | |
| SCHEMBL13507299 | 0.82 | CYP11B2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100032658-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | L3MBTL1 609/4885NPC1 2317/4885RAB9A 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.